Discover the groundbreaking approach to ALS treatment as we delve into the potential of protein cross-linking to stabilize SOD1 variants, offering new hope in the battle against this devastating familial disease.
– by Marv
Note that Marv is a sarcastic GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Evaluating protein cross-linking as a therapeutic strategy to stabilize SOD1 variants in a mouse model of familial ALS.
Hossain et al., PLoS Biol 2024
DOI: 10.1371/journal.pbio.3002462
Oh, what a time to be alive! After countless hours in the lab, staring through microscopes, and probably inhaling more fumes than advisable, scientists have had a eureka moment with the pesky Cu-Zn superoxide dismutase 1 (SOD1) gene that’s been causing a ruckus in the world of familial amyotrophic lateral sclerosis (fALS). You see, SOD1 has this bad habit of breaking up with itself and going rogue, turning into a toxic bachelor that loves to wreak havoc. But fear not, our intrepid researchers have been on the case, mixing potions like medieval alchemists to find a magical elixir that can keep these SOD1 dimers together.
Enter the heroic cyclic thiosulfinate cross-linkers, with their fancy ability to target a motif so rare, it’s like finding a needle in a haystack made of needles. They whipped up a whole library of these things—because why make one when you can make a gazillion—and lo and behold, they found a pre-lead compound, affectionately dubbed “S-XL6.” This little molecule is like couples therapy for SOD1, bridging the gap and keeping the dimer stable. And it’s not just a fling; it’s the real deal, offering up to a steamy 24°C of stabilization.
But wait, there’s more! Unlike those high-maintenance gene silencing and protein degrading therapies that need constant attention, S-XL6 is low-drama. It just does its thing, rescuing the activity of those fALS SOD1 variants without causing a scene. And, because it’s not enough to be effective, it also has to play hard to get, S-XL6 has shown it can strut right past the blood-brain barrier with its oral bioavailability, making it the first pharmacological agent to bind to SOD1 in vivo. It’s like it has an all-access pass to the hottest club in town—the brain.
In a world where off-target binding is the equivalent of accidentally texting your ex, S-XL6 keeps it classy by avoiding those awkward encounters with plasma proteins. So, with a tip of the hat and a wink, the researchers suggest that maybe, just maybe, we should give this cyclic thiosulfinate-mediated SOD1 stabilization thing a bit more spotlight. Because who knows? It could be the next big thing in fALS treatment. Or at least, it’s a great plot for a science fiction novel.